6 results on '"Lokesh Kumar Bhatt"'
Search Results
2. Emerging targets signaling for inflammation in Parkinson’s disease drug discovery
- Author
-
Rhema Chandan Khairnar, Niraj Parihar, Kedar S. Prabhavalkar, and Lokesh Kumar Bhatt
- Subjects
Cellular and Molecular Neuroscience ,Neurology (clinical) ,Biochemistry - Published
- 2022
3. Deubiquitylating enzymes: potential target in autoimmune diseases
- Author
-
Lokesh Kumar Bhatt and Niraj Parihar
- Subjects
medicine.medical_specialty ,Ubiquitin-Protein Ligases ,Immunology ,Autoimmune Diseases ,Immune tolerance ,Immune system ,Ubiquitin ,Internal medicine ,medicine ,Animals ,Humans ,Pharmacology (medical) ,Molecular Targeted Therapy ,Pharmacology ,Deubiquitinating Enzymes ,biology ,Ubiquitination ,Rheumatology ,Cell biology ,Transport protein ,Proteasome ,Disease Progression ,biology.protein ,Target protein ,Deubiquitination - Abstract
The ubiquitin-proteasome pathway is responsible for the turnover of different cellular proteins, such as transport proteins, presentation of antigens to the immune system, control of the cell cycle, and activities that promote cancer. The enzymes which remove ubiquitin, deubiquitylating enzymes (DUBs), play a critical role in central and peripheral immune tolerance to prevent the development of autoimmune diseases and thus present a potential therapeutic target for the treatment of autoimmune diseases. DUBs function by removing ubiquitin(s) from target protein and block ubiquitin chain elongation. The addition and removal of ubiquitin molecules have a significant impact on immune responses. DUBs and E3 ligases both specifically cleave target protein and modulate protein activity and expression. The balance between ubiquitylation and deubiquitylation modulates protein levels and also protein interactions. Dysregulation of the ubiquitin-proteasome pathway results in the development of various autoimmune diseases such as inflammatory bowel diseases (IBD), psoriasis, multiple sclerosis (MS), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). This review summarizes the current understanding of ubiquitination in autoimmune diseases and focuses on various DUBs responsible for the progression of autoimmune diseases.
- Published
- 2021
4. Novel Targets for Hypertension Drug Discovery
- Author
-
Lokesh Kumar Bhatt, Ishant Selokar, Dezaree Raut, and Tahir Hussain
- Subjects
Blood Pressure ,030204 cardiovascular system & hematology ,Bioinformatics ,Coronary artery disease ,03 medical and health sciences ,0302 clinical medicine ,Drug Discovery ,Internal Medicine ,medicine ,Humans ,Chemerin ,030212 general & internal medicine ,Myocardial infarction ,Stroke ,Antihypertensive Agents ,Apelin receptor ,biology ,business.industry ,Angiotensin II ,medicine.disease ,Comorbidity ,Blood pressure ,Cardiovascular Diseases ,Heart failure ,Hypertension ,biology.protein ,Chemokines ,business - Abstract
Despite the availability of various medications and prescribing combination therapies, uncontrolled blood pressure and resistance are observed in more than 40% of patients. The purpose of this review is to discuss emerging novel approaches for the treatment of hypertension and propose future research and clinical directions. Hypertension is a common disease of the cardiovascular system which may arise solely or as a comorbidity of other disorders. It is a crucial risk factor for cardiovascular diseases such as coronary artery disease, myocardial infarction, congestive heart failure, renal failure, and stroke. The results from current literature regarding the novel approaches showed several targets that could be explored as potential therapeutic options. These include toll-like receptor 4, a critical regulator of angiotensin II–induced hypertension; protease-activated receptor 2, which promotes collagen deposition and inflammatory responses; chemerin, which causes metabolic and obesity-associated hypertension; apelin receptor; transient receptor potential melastatin; urotensin-II; and Tie2 receptor. This review discusses various targets and pathways that could be emerging pharmacological therapies for hypertension.
- Published
- 2021
5. Biomarkers for Parkinson’s Disease: Recent Advancement
- Author
-
Lokesh Kumar Bhatt, Kedar S. Prabhavalkar, and Sharvari Lotankar
- Subjects
0301 basic medicine ,Pathology ,medicine.medical_specialty ,Neurology ,Parkinson's disease ,Physiology ,Neuroimaging ,Review ,Comorbidity ,Disease ,Bioinformatics ,medicine.disease_cause ,Neuroprotection ,03 medical and health sciences ,0302 clinical medicine ,Degenerative disease ,Hypokinesia ,medicine ,Humans ,Biomarker discovery ,business.industry ,General Neuroscience ,Parkinson Disease ,General Medicine ,medicine.disease ,030104 developmental biology ,medicine.symptom ,business ,Biomarkers ,030217 neurology & neurosurgery ,Oxidative stress - Abstract
As a multi-factorial degenerative disease, Parkinson's disease (PD) leads to tremor, gait rigidity, and hypokinesia, thus hampering normal living. As this disease is usually detected in the later stages when neurons have degenerated completely, cure is on hold, ultimately leading to death due to the lack of early diagnostic techniques. Thus, biomarkers are required to detect the disease in the early stages when prevention is possible. Various biomarkers providing early diagnosis of the disease include those of imaging, cerebrospinal fluid, oxidative stress, neuroprotection, and inflammation. Also, biomarkers, alone or in combination, are used in the diagnosis and evolution of PD. This review encompasses various biomarkers available for PD and discusses recent advances in their development.
- Published
- 2017
6. Minocycline with aspirin: a therapeutic approach in the treatment of diabetic neuropathy
- Author
-
Lokesh Kumar Bhatt and Addepalli Veeranjaneyulu
- Subjects
Male ,medicine.medical_specialty ,Diabetic neuropathy ,Neurology ,Matrix metalloproteinase inhibitor ,Minocycline ,Dermatology ,Matrix Metalloproteinase Inhibitors ,Pharmacology ,Diabetes Mellitus, Experimental ,Therapeutic approach ,Diabetic Neuropathies ,Diabetes mellitus ,medicine ,Animals ,Cyclooxygenase Inhibitors ,Protease Inhibitors ,Rats, Wistar ,Latency (engineering) ,Aspirin ,business.industry ,General Medicine ,medicine.disease ,Matrix Metalloproteinases ,Rats ,Psychiatry and Mental health ,Anesthesia ,Drug Therapy, Combination ,Neurology (clinical) ,business ,medicine.drug - Abstract
Enhanced production of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) in diabetes leads to degradation of extracellular matrix in blood vessels and leads to complications of diabetes. In the present study, we have targeted MMP-2 and MMP-9 overactivation in diabetic neuropathy using a known MMP-2 and MMP-9 inhibitor, minocycline, with a non-selective COX inhibitor, aspirin. Streptozotocin-induced diabetic neuropathy was carried out in male Wistar rats and monitored by measuring the sensory nerve conduction velocity (SNCV), motor nerve conduction velocity (MNCV), tail flick latency and hot plate latency. Three weeks of treatment with a combination of minocycline and aspirin showed significant improvement in SNCV, MNCV, hot plate latency and tail flick latency when compared with diabetic control. The results of the present study suggest that MMP-2 and MMP-9 inhibition in the presence of COX inhibitor prevents the development of experimental diabetic neuropathy in rats and can be a potential approach for the treatment.
- Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.